Interim analyses of an ongoing clinical trial (NCT02637934) evaluating [18F]PARP1‐inhibitor PET in ovarian cancer compared results of [18F]PARP1‐inhibitor PET with [18F]FDG PET in eight and 14 patients, respectively [65, 66]. This evidence concerns the gene PARP1 and ovarian carcinoma.